SARS-COV-2 IgG antibody response in pregnant women at delivery - 20/08/21

Doi : 10.1016/j.jogoh.2020.102041

Vassilis Tsatsaris ^a,^b,⁎ , Alice-Andrée Mariaggi ^a,^c,^{^{1
Both authors contributed equally to the work.}}, Odile Launay ^a,^d,^{^{1
Both authors contributed equally to the work.}}, Camille Couffignal ^a,^e, Jessica Rousseau ^f, Pierre Yves Ancel ^a,^f, Estelle Marcault ^a,^e, Yves Ville ^a,^g, Anne-Gaël Cordier ^h, Alexandre Vivanti ^i,^j, Julie Carrara ^j, Dominique Luton ^a,^k,^s, Marc Dommergues ^l,^m, Constance Borie ^a,ⁿ, Gilles Kayem ^l,^o, Vivien Alessandrini ^a,^b, Laurence Lecomte ^f, Jean François Meritet ^b, Marianne Leruez-Ville ^p, François Goffinet ^a,^b, Claire Dubois ^a,^q, Olivier Picone ^a,^r, Christelle Vauloup Fellous ^i,^q
^a Université de Paris, F-75006 Paris, France
^b Maternité Port-Royal, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
^c Laboratoire de Virologie, AP-HP, Hôpital Cochin, F-75014 Paris, France
^d CIC vaccinologie, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
^e Unité de recherche clinique PNVS, AP-HP, Hôpital Bichat, F-75018 Paris, France
^f Unité de recherche clinique, CIC-Mère enfant, AP-HP, FHU PREMA, Hôpital Cochin, F-75014 Paris, France
^g Maternité, AP-HP, Hôpital Necker, F-75007 Paris, France
^h Maternité, AP-HP, Hôpital Bicêtre, F-94270 Le Kremlin-Bicêtre, France
ⁱ Université Paris-Saclay, 94804 Villejuif, France
^j Maternité, AP-HP, Hôpital Antoine Béclère, F-92140 Clamart, France
^k Maternité, AP-HP, Hôpital Bichat, F-75018 Paris, France
^l Sorbonne Université, F-75006 Paris, France
^m Maternité, AP-HP, Hôpital Pitié-Salpêtrière, F-75013 Paris, France
ⁿ Maternité, AP-HP, Hôpital Robert Debré, F-75019 Paris, France
^o Maternité, AP-HP, Hôpital Trousseau, F-75012 Paris, France
^p Laboratoire de Virologie, AP-HP, Hôpital Necker, F-75007 Paris, France
^q Laboratoire de Virologie, AP-HP, Hôpital Paul-Brousse, F-94804 Villejuif, France
^r Maternité, AP-HP, Hôpital Louis Mourier, F-75007 Paris, France
^s Groupe de Recherche sur les Infections pendant la Grossesse (GRIG), France

^⁎Corresponding author at: Hôpital Cochin, Maternité Port-Royal, AP-HP, FHU PREMA, Université de Paris, 123 Bd Port-Royal F-75014 Paris, France.Hôpital CochinMaternité Port-RoyalAP-HP, FHU PREMAUniversité de Paris123 Bd Port-RoyalParisF-75014France

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

The prevalence of COVID-19 infection during pregnancy is not known. COVIPREG is a prospective French multicenter study to assess the seroprevalence at the time of delivery and the maternal and neonatal impact of COVID-19 infection during pregnancy. In order to study factors associated with poor outcomes after COVID-19 Infection during pregnancy and adapt the sample size of the study, a preliminary assessment of the prevalence of SARS-CoV-2 IgG was planned after 500 inclusions in a one perinatal center of Paris area.

Objectives

To assess the prevalence of SARS-CoV-2 IgG antibody response in pregnant women at the time of delivery during the COVID-19 pandemia.

Study design

A prospective observational study at Cochin hospital (Level III maternity). Patients admitted for delivery were offered to participate to the study. Each patient participating to the study was tested for anti-SARS-CoV-2-IgG antibodies using a commercially available ELISA.

Results

Among the 529 patients included in the COVIPREG study between April 29 and June 26, 529 were assessed for SARS-CoV-2 IgG antibody response and 25 had a positive test, ie 4.7 % with a confidence interval at 95 % [3.0 %–6.9 %]).

Conclusions

Four months after the beginning of the infection in Paris, the seroprevalence of SARS-CoV-2 IgG in pregnant women at the time of delivery is low. Studies evaluating the impact of COVID-19 infection during pregnancy should take this information in account in order to adapt the sample size.

Le texte complet de cet article est disponible en PDF.

Keywords : Pregnancy, COVID-19, SARS-CoV-2, Seroprevalence

Plan

Introduction

Methods

Patients populations

Serology testing for SARS-CoV-2 specific IgG

Export

Vol 50 - N° 7

Article 102041- septembre 2021 Retour au numéro

Article précédent

Angiographic findings and outcomes after embolization of patients with suspected postabortion uterine arteriovenous fistula
Alizé Gilbert, Thibault Thubert, Vincent Dochez, Anne-Sophie Riteau, Mathilde Ducloyer, Paul Ragot, Eric Frampas, Frédéric Douane, Arthur David

| Article suivant

Screening for cancers of the cervix and vagina for women exposed to diethylstilbestrol (DES) in utero
Michel Tournaire, Emmanuel Devouche, Nathalie Lafaye, Anne Levadou

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

SARS-COV-2 IgG antibody response in pregnant women at delivery - 20/08/21

Abstract

Background

Objectives

Study design

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL